Nomination committee for the 2023 Annual General Meeting

According to the resolution of the 2022 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of the number of votes at the end of December 2022.

At the end of December, the three largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB and Sten Irwe. All have agreed to participate in the nomination committee's work

Prior to the 2023 Annual General Meeting, the Nomination Committee consists of Christer Fåhraeus (appointed by Fårö Capital AB), Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and Sten Irwe.

Shareholders who wish to submit proposals to the Nomination Committee are encouraged to send an e-mail to info@eqlpharma.com.

For further information, please contact:
Axel Schörling
CEO & President, EQL Pharma AB (publ)

Phone: +46 (0) 763 – 17 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.